TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: I-SIGHT: Interactive Study to Increase Glaucoma adHerence to Treatment Phase 2: Participant Recruitment & Intervention Delivery and Evaluation
Brief Summary: Study participants who receive the I-SIGHT intervention will have higher rates of glaucoma treatment compliance (e.g., medication-taking and refill compliance, return for clinical follow-up) and more positive eye health outcomes at 12-month follow-up than participants who receive the control group intervention.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
B: Arm Label: Telephone and print based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone and Print based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telephone and Print based intervention; Assigned to Arm(s): Telephone and print based intervention
C: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
D: Arm Label: Smartphone-supplemented iCBT with therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-supplemented iCBT, Behavioral: Therapist support | Arm Label: Smartphone-supplemented iCBT without therapist support; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-supplemented iCBT | Arm Label: Active waiting list control group with delayed treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smartphone-supplemented iCBT, Other: Active waiting list | Intervention Type: BEHAVIORAL; Name: Smartphone-supplemented iCBT; Assigned to Arm(s): Active waiting list control group with delayed treatment, Smartphone-supplemented iCBT with therapist support, Smartphone-supplemented iCBT without therapist support | Intervention Type: BEHAVIORAL; Name: Therapist support; Assigned to Arm(s): Smartphone-supplemented iCBT with therapist support | Intervention Type: OTHER; Name: Active waiting list; Assigned to Arm(s): Active waiting list control group with delayed treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing
Brief Summary: The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.


Options:
A: Arm Label: Telemedicine-Based Collaborative Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Telemedicine-Based Collaborative Care | Arm Label: Practice Based Collaborative Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Practice Based Collaborative Care | Intervention Type: OTHER; Name: Telemedicine-Based Collaborative Care; Assigned to Arm(s): Telemedicine-Based Collaborative Care | Intervention Type: OTHER; Name: Practice Based Collaborative Care; Assigned to Arm(s): Practice Based Collaborative Care
B: Arm Label: Arm 1: Depression Collaborative Care; Type: EXPERIMENTAL; Interventions: Other: Depression collaborative care model | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression collaborative care model; Assigned to Arm(s): Arm 1: Depression Collaborative Care
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telemedicine intervention | Intervention Type: BEHAVIORAL; Name: Telemedicine intervention; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing
Brief Summary: The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.


Options:
A: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group
C: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Arm Label: Standard Care and Pharmaceutical Care; Type: OTHER; Interventions: Other: Standard care and Pharmaceutical care | Intervention Type: OTHER; Name: Standard care and Pharmaceutical care; Assigned to Arm(s): Standard Care and Pharmaceutical Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
D: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing
Brief Summary: The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Extended Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference, Behavioral: Comprehensive Medication Management | Arm Label: Usual Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference | Intervention Type: DEVICE; Name: Glucose and lipids; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Glycosylated Hemoglobin A1c; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Blood Pressure and Heart Rate; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Body mass index; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Waist and Hip circumference; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: BEHAVIORAL; Name: Comprehensive Medication Management; Assigned to Arm(s): Extended Treatment Group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmaceutical care program for antidepressant treatment | Intervention Type: BEHAVIORAL; Name: Pharmaceutical care program for antidepressant treatment; Assigned to Arm(s): Intervention Group
D: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Arm Label: Standard Care and Pharmaceutical Care; Type: OTHER; Interventions: Other: Standard care and Pharmaceutical care | Intervention Type: OTHER; Name: Standard care and Pharmaceutical care; Assigned to Arm(s): Standard Care and Pharmaceutical Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial Investigating a Mobile Phone Self-monitoring Tool (Mobiletype) to Increase Emotional Self-awareness and Reduce Depressive Symptoms in Young People.
Brief Summary: The mobiletype program is a mental health assessment and monitoring tool that runs on mobile phones.

The program assesses the general mental health of young people in real-time and transmits this data to a website to be reviewed by their general practitioner (GP) in consultation with their patient. The website consists of individualised feedback reports for each participant, and graphical displays of the monitoring data. The primary aims of the current project are to examine: (1) whether the process of self-monitoring via the mobiletype program increases young people's awareness of their mood and reduces depressive symptoms and (2) whether emotional self-awareness mediates the relationship between self-monitoring and depressive symptoms.


Options:
A: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic Self-Report Assessment - Cancer (ESRA-C); Assigned to Arm(s): Intervention
C: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring
D: Arm Label: MONARCA; Type: ACTIVE_COMPARATOR; Interventions: Device: MONARCA | Arm Label: NON-MONARCA; Type: PLACEBO_COMPARATOR; Interventions: Device: NON-MONARCA | Intervention Type: DEVICE; Name: MONARCA; Assigned to Arm(s): MONARCA | Intervention Type: DEVICE; Name: NON-MONARCA; Assigned to Arm(s): NON-MONARCA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial Investigating a Mobile Phone Self-monitoring Tool (Mobiletype) to Increase Emotional Self-awareness and Reduce Depressive Symptoms in Young People.
Brief Summary: The mobiletype program is a mental health assessment and monitoring tool that runs on mobile phones.

The program assesses the general mental health of young people in real-time and transmits this data to a website to be reviewed by their general practitioner (GP) in consultation with their patient. The website consists of individualised feedback reports for each participant, and graphical displays of the monitoring data. The primary aims of the current project are to examine: (1) whether the process of self-monitoring via the mobiletype program increases young people's awareness of their mood and reduces depressive symptoms and (2) whether emotional self-awareness mediates the relationship between self-monitoring and depressive symptoms.


Options:
A: Arm Label: Standard; Type: EXPERIMENTAL; Interventions: Behavioral: Standard | Arm Label: Technology Supported condition; Type: EXPERIMENTAL; Interventions: Behavioral: Technology Supported | Arm Label: Self-Guided; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Technology Supported; Assigned to Arm(s): Technology Supported condition | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Standard
B: Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)
C: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
D: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial Investigating a Mobile Phone Self-monitoring Tool (Mobiletype) to Increase Emotional Self-awareness and Reduce Depressive Symptoms in Young People.
Brief Summary: The mobiletype program is a mental health assessment and monitoring tool that runs on mobile phones.

The program assesses the general mental health of young people in real-time and transmits this data to a website to be reviewed by their general practitioner (GP) in consultation with their patient. The website consists of individualised feedback reports for each participant, and graphical displays of the monitoring data. The primary aims of the current project are to examine: (1) whether the process of self-monitoring via the mobiletype program increases young people's awareness of their mood and reduces depressive symptoms and (2) whether emotional self-awareness mediates the relationship between self-monitoring and depressive symptoms.


Options:
A: Arm Label: CATCH-IT; Type: EXPERIMENTAL; Interventions: Behavioral: CATCH-IT | Arm Label: Health Education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CATCH-IT; Assigned to Arm(s): CATCH-IT
B: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive/expressive (S/E) therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bibliotherapy | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive/expressive (S/E) therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Bibliotherapy; Assigned to Arm(s): 3
D: Arm Label: Mindfulness-based stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Arm Label: Healthy Topics; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): Healthy Topics, Mindfulness-based stress reduction

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial
Brief Summary: The EVITA study is a clinical trial that will test the effect of varenicline (Champix™), a new drug used to help people quit smoking, in patients who have suffered a heart attack. Varenicline has been recently shown to increase the number of otherwise healthy people who quit smoking compared to placebo (sugar pill). Although varenicline has been shown to reduce smoking in healthy populations, its effectiveness in patients recovering from a heart attack is unknown. The EVITA trial will help answer this question.

A total of 300 patients who have recently suffered a heart attack and are active smokers will be recruited in the study. For twelve weeks, half the patients will receive varenicline and the other half will receive placebo pills. Patients will be followed for a period of 12 months. During this time, patients will receive telephone calls and go to clinic visits in order to assess if they are smoking. These follow-ups will also assess any side effects and clinical events such as another heart attack or hospitalization that patients may have had. Smoking cessation will be checked using exhaled carbon monoxide readings and self-reports.

The EVITA trial will be the first study to examine the use of varenicline in patients who have recently had a heart attack. These patients, if they continue to smoke, are at high risk of having another cardiac event. If varenicline is shown to be useful in this population, it will have a major impact on prevention of cardiac events in patients who have suffered a heart attack.


Options:
A: Arm Label: varenicline with counselling; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo with counselling; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline with counselling | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo with counselling
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD
Brief Summary: This study will determine the advantages and disadvantages of adding one of two different types of drugs to stimulant treatment for reducing aggressive behavior in children with attention deficit with hyperactivity disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mixed Amphetamine Salts; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Counseling; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Behavior Management Training with Parents; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate, Drug: Risperidone, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Valproate, Drug: Risperidone, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Stimulant medication, Behavioral: Behavioral family counseling | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Stimulant medication; Assigned to Arm(s): 1, 2, 3 | Intervention Type: BEHAVIORAL; Name: Behavioral family counseling; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa
Brief Summary: A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa


Options:
A: Arm Label: infliximab; Type: EXPERIMENTAL; Interventions: Drug: infliximab, Drug: Placebo Comparator | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): infliximab | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo, infliximab
B: Arm Label: placebo controlled; Type: N/A; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): placebo controlled
C: Intervention Type: PROCEDURE; Name: Long-pulsed Nd:YAG laser 1064 nm; Assigned to Arm(s): N/A
D: Arm Label: Adalimumab 40 mg qwk; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg qwk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A